



Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference

August 4, 2026

LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat and host in-person 1x1 investor meetings at Canaccord Genuity's 46th Annual Growth Conference, which will be held from August 11-12, 2026.

Canaccord Genuity's 46th Annual Growth Conference

Fireside Chat Date: Wednesday, August 12, 2026

Fireside Chat Time: 3:30 PM ET

Location: InterContinental Boston, Boston, MA

The presentation will be webcast live and available for replay under "News & Events" in the Investors section of Biodesix website at [Biodesix.com](https://www.biodesix.com).

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. **Biodesix Diagnostic Tests**, including Nodify Lung[®] Nodule Risk Assessment and IQLung[®] Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. **Biodesix Development Services** enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit [biodesix.com](https://www.biodesix.com).

Biodesix Contacts:

Media:

Natalie St. Denis, Director Corporate Communications

natalie.stdenis@biodesix.com

(720) 925-9285

Investors:

Chris Brinzey, Partner, ICR

chris.brinzey@icrhealthcare.com

(339) 970-2843